Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TWK10-fermented soymilk ethanol extract
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Topical
01
Overview
TWK10-fermented soymilk ethanol extract is an ethanol-based extract derived from soymilk fermented with the probiotic strain Lactobacillus plantarum TWK10. This functional food ingredient has demonstrated a range of bioactivities in preclinical studies, including antioxidant, anti-inflammatory, anti-hypertensive, memory-enhancing, and wound-healing effects. The mechanism of action is believed to involve enhancement of antioxidant capacity (via increased flavonoid and phenolic content), reduction of oxidative stress markers, modulation of inflammation-associated proteins, and improvement in cognitive function in animal models. It has been studied primarily as a dietary supplement or nutraceutical for potential benefits in conditions such as hypertension-induced vascular dementia and diabetes-related cognitive impairment[3][4][6].
- Other names
- ETFSMTWK10-fermented soymilk extractTWK-10-fermented soymilk extractTWK 10-fermented soymilk extract
02
Targets
ACE (Angiotensin Converting Enzyme)
Beyond the preview
Go deeper on TWK10-fermented soymilk ethanol extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TWK10-fermented soymilk ethanol extract.